RxDoctor Payments Data

Leila Vizirov, MD

Family Medicine · Houston, TXNPI 1770571895

Payments from drug & device makers

$1,350in general payments, 2019–2025

Across 66 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$295
  • AbbVie$244
  • Pfizer$176
  • Novo Nordisk$164
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$94
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$82
  • plus $296 from 9 others

What the payments were for

  • Food & beverage$1,30597%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,350 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$41,821
Medicare patients
102
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$105,256
JanuviaSitagliptin Phosphate48$55,787
JardianceEmpagliflozin25$28,521
TrulicityDulaglutide20$25,764
LinzessLinaclotide26$22,555
FarxigaDapagliflozin Propanediol18$17,471
XareltoRivaroxaban24$14,414
EliquisApixaban22$12,602
MounjaroTirzepatide11$11,660
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,069
Tresiba Flextouch U-100Insulin Degludec13$7,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,763
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,857
Gabapentin178$2,120
Megestrol Acetate21$1,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$164$105,25671 claims
Lilly USA, LLCTrulicity, Mounjaro$295$37,42431 claims
Boehringer IngelheimJardiance$37$28,52125 claims
AbbVieLinzess$244$22,55526 claims
Johnson & JohnsonXarelto$29$14,41424 claims
PfizerEliquis$176$12,60222 claims
GSKTrelegy Ellipta$59$6,76311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →